Olmesartan/Amlodipine Clonmel (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine Clonmel, is an angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond monotherapy.

GNH USA supplies Olmesartan/Amlodipine Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipine Clonmel is used in cardiovascular therapy, targeting elevated blood pressure and related conditions. - Hypertension: Improves blood pressure control when monotherapy is insufficient. - Hypertensive heart disease: Reduces cardiac workload and risk of progression. - Chronic kidney disease with hypertension: Helps slow renal function decline associated with high blood pressure.

Adverse reactions may occur with any antihypertensive combination therapy.

Common Side Effects: - Dizziness or light‑headedness - Peripheral edema - Headache - Flushing - Fatigue - Nasal congestion

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Hepatic enzyme elevation - Jaundice - Acute kidney injury - Myocardial infarction in susceptible patients

When prescribing Olmesartan/Amlodipine Clonmel, clinicians should consider several safety aspects. - Monitor renal function: Assess serum creatinine and electrolytes before and during therapy. - Check potassium levels: Hyper‑kalaemia risk may increase when combined with potassium‑sparing agents. - Assess for pregnancy: Avoid use in pregnancy due to fetal toxicity. - Evaluate hepatic status: Use caution in patients with liver impairment. - Review concomitant antihypertensives: Risk of additive hypotension. - Store below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipine Clonmel can interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): Increases risk of renal impairment and hyper‑kalaemia. - Potassium‑rich supplements or potassium‑sparing diuretics: Heightens hyper‑kalaemia risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): May blunt antihypertensive effect and affect renal function. - CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): Can raise amlodipine plasma levels. - Diuretics: May potentiate hypotensive response. - Lithium: May increase serum lithium concentrations. - Alcohol: Enhances vasodilatory effect, increasing dizziness.